

REMARKS

Reconsideration is requested.

Claims 17-19 are pending.

Claim 17 has been amended to recite the active portion of SEQ ID NO:1 as further explained below and as appears to have been recognized by the Examiner. The recitation of a portion of a sequence listed in a Sequence Listing is submitted to be an appropriate format, as explained in MPEP § 2422.03 ("Sequence identifiers can also be used to discuss and/or claim parts or fragments of a properly presented sequence. For example, language such as "residues 14 to 243 of SEQ ID NO:23" is permissible and the fragment need not be separately presented in the "Sequence Listing." "

(http://www.uspto.gov/web/offices/pac/mpep/documents/2400_2422_03.htm#sect2422.03 (July 10, 2006)).

Withdrawal of the previous rejections is acknowledged, with appreciation.

The Section 112, first paragraph "enablement", rejection of claims 17-19 is obviated by the above amendments. Specifically, as acknowledged by the Examiner, the specification teaches that the biologically active human PTX3 lacks the leader sequence of the full length sequence of SEQ ID NO:1. The applicant notes that page 12, lines 18-20 of the specification describes that the leader sequence of SEQ ID NO:1 is shown as the underlined sequence in sheet 5 of 6 of the figures of the originally-published application (WO99/32516). Moreover, the applicant notes that page 7, lines 4-11 of the application as published reports the following:

"Production of recombinant PTX3: a fragment containing the complete cDNA sequence of human PTX3 (sequence 2 and Fig. 6) was subcloned in the BamH1 site of the

expression vector pSG5 (Fig. 1) (Stratagene, La Jolla, CA, USA) and transfected in CHO cells using the precipitated calcium procedure. A clone selected in G418, capable of producing large amounts of PTX3, was used as a source from which the protein was purified by chromatography by means of ion exchange and gel filtration" (emphasis added).

No new matter has been added by the above amendments. The claims are submitted to be supported by an enabling disclosure.

Withdrawal of the Section 112, first paragraph "enablement", rejection is requested.


The Examiner is requested to contact the undersigned in the event anything further is required.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100